Roche fenebrutinib NDA accepted by FDA for RMS and PPMS
Roche has announced that the US Food and Drug Administration has accepted the company's New Drug Application for fenebrutinib under priority review, covering both relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). If approved, fenebrutinib would be the first BTK inhibitor and, the company says, the first high-efficacy oral treatment indicated across both forms of the disease.
The filing is backed by three Phase III trials. In the FENhance 1 and 2 RMS studies, fenebrutinib reduced the annualised relapse rate by 51% and 58.5% respectively versus teriflunomide over 96 weeks, with both results reaching statistical significance. Roche noted that the relapse rate observed translates to approximately one relapse every 17 years, which it describes as the lowest seen in any Phase III MS programme. Disability progression measures, including 12-week composite confirmed disability progression, showed consistent positive trends favouring fenebrutinib, though no statistically significant disability endpoint was reported in the RMS studies.
PPMS results and safety profile
In the FENtrepid PPMS trial, fenebrutinib met its primary endpoint of non-inferiority to ocrelizumab (Ocrevus), currently the only approved therapy for PPMS. Fenebrutinib numerically reduced the risk of disability progression by 12% versus Ocrevus, with a hazard ratio of 0.88 (95% CI: 0.75 to 1.03) and curves separating from 24 weeks. The non-inferiority design means the result establishes comparable efficacy rather than superiority, a distinction the market will weigh when considering uptake against an already well-established infused standard of care.
Safety data across the three trials showed comparable serious adverse event rates between fenebrutinib and comparators in both indications: 9% versus 9% and 11% versus 6% in FENhance 1 and 2 respectively, and 19% versus 19% in FENtrepid. Liver enzyme elevations were observed more frequently with fenebrutinib than with Ocrevus in the PPMS study. Roche acknowledged an imbalance in reported fatalities across the three trials, attributing this to different timepoints and causes. The company characterised the overall safety profile as manageable across a database of more than 2,700 participants.
Levi Garraway, Roche's Chief Medical Officer, said that three Phase III studies had "demonstrated the potential for fenebrutinib to address both relapsing and progressive disease, thereby bringing us closer to an oral treatment that could make a meaningful difference across the MS spectrum."
Market context and competitive landscape
The MS treatment market is large and fiercely contested. Roche's own ocrelizumab has treated more than 525,000 patients since its approval, but the company's chief executive for pharmaceuticals, Teresa Graham, noted that over a third of people with MS remain on lower-efficacy therapies. An oral, high-efficacy option that addresses both RMS and PPMS simultaneously would represent a meaningful commercial and clinical step change, particularly for PPMS, where patients have had only one approved option for nearly a decade.
The BTK inhibitor class has attracted substantial development investment across MS and other autoimmune indications, with several companies having pursued covalent BTK inhibitors in the disease, a number of which have previously reported disappointing Phase III results. Fenebrutinib's non-covalent, reversible mechanism is positioned as a differentiator, allowing CNS penetration and targeting of both peripheral B cells and brain-resident microglia. Whether this translates to a durable commercial advantage will depend on the final label, the PDUFA date Roche has not yet disclosed, and the price and payer dynamics of competing against a well-entrenched infused therapy. Specialist neurologists will be looking closely at the full dataset, particularly the fatality imbalance and liver enzyme signal, before making prescribing decisions.